This study revealed that patients with a low number of MMP-2 positive cells (5–20%) in the tumor sample survived as well as those with an MMP-2 negative melanoma (10 year disease-specific survival rate of 79%), whereas patients with a primary tumor with high MMP-2 expression (>20% of tumor cells) had a 10-year disease-specific survival rate of 51% (207). This evidence concerns the gene MMP2 and neoplasm.